Swiss National Bank
LENZ

Swiss National Bank’s LENZ Therapeutics LENZ Stock Holding History

Swiss National Bank’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,800
Closed -$199K – 2357
2026
Q1 		$199K Hold
21,800
– – ﹤0.01% 2300
2025
Q4 		$349K Hold
21,800
– – ﹤0.01% 2306
2025
Q3 		$1.02M Buy
21,800
+500
+2% +$18.4K ﹤0.01% 2159
2025
Q2 		$624K Hold
21,300
– – ﹤0.01% 2286
2025
Q1 		$548K Buy
21,300
+2,400
+13% +$59.1K ﹤0.01% 2327
2024
Q4 		$546K Buy
+18,900
New +$576K ﹤0.01% 2392

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Swiss National Bank's LENZ Position: Q2 2026 in Review

Swiss National Bank sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 21,800 shares — an estimated $199K sold.

Swiss National Bank first reported a position in LENZ in Q4 2024 and held it in 6 quarters. The position peaked at $1.02M in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Swiss National Bank reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Swiss National Bank sold 21,800 LENZ Therapeutics shares in Q2 2026, an estimated $199K.
  • Swiss National Bank first reported a position in LENZ Therapeutics in Q4 2024 and held it in 6 quarters.
  • Swiss National Bank's LENZ Therapeutics position peaked at $1.02M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.